doi:10.3969/j.issn.1673-8640.2021.01.023

Abstract

CLC Number:

R446.1

Figures/Tables 3

References 13

[1]	韩静静,曹霞,周晨亮,等. 多重耐药菌导致呼吸机相关性肺炎的危险因素及病原菌分析[J]. 医药导报,2019,38(10):1335-1338.
[2]	中华医学会呼吸病学分会. 社区获得性肺炎诊断和治疗指南[J]. 中华结核和呼吸杂志,2006,29(10):651-655
[3]	陈新谦,金有豫,汤光. 新编药物学(第16版) [M]. 北京:人民卫生出版社,2007.
[4]	张智琪,陈孟莉. 2011—2013年我院常用麻醉药品应用分析[J]. 中国药物应用与监测,2015,12(4):242-245.
[5]	宗春光,李军,陶晓明,等. 老年患者广泛耐药鲍曼不动杆菌血行感染及死亡危险因素[J]. 中国老年学杂志,2019,39(18):4505-4507.
[6]	CHO J C,ZMARLICKA M T,SHAEER K M,et al.Meropenem/vaborbactam,the first carbapenem/β-lactamase inhibitor combination[J]. Ann Pharmacother,2018,52(8):769-779.
[7]	WU G,CHEON E.Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis[J]. Expert Opin Pharmacother,2018,19(13):1495-1502.
[8]	YU Z,PANG X,WU X,et al.Clinical outcomes of prolonged infusion(extended infusion or continuous infusion)versus intermittent bolus of meropenem in severe infection:a meta-analysis[J]. PLoS One,2018,13(7):e0201667.
[9]	汤雨晴,叶倩,郑维义. 抗生素类药物的研究现状和进展[J]. 国外医药(抗生素分册),2019,40(4):295-301.
[10]	ZHAO W,WANG B,YU G.Antibiotic resistance genes in China:occurrence,risk,and correlation among different parameters[J]. Environ Sci Pollut Res Int,2018,25(22) :21467-21482.
[11]	陈旎旎,吴艳琴,余文浩. 氟喹诺酮类抗菌药物治疗卒中相关性肺炎的安全性评价[J]. 中国实用医药,2019,14(24):88-89.
[12]	孙晓娈,王莹,李歆. 江苏省47家三级医院抗菌药物利用与趋势分析[J]. 中国现代应用药学,2019,36(19):2478-2484.
[13]	许书花,冯锦辉,黄韫,等. 我院2015~2016年辅助用药情况分析[J]. 海峡药学,2017,29(7):248-250.

抗菌药物类别	种类数/种	药物名称
青霉素类	2	美洛西林-舒巴坦、哌拉西林-他唑巴坦
头孢菌素类	8	头孢替安、头孢曲松、头孢呋辛、头孢美唑、头孢替唑、头孢唑林、头孢哌酮-舒巴坦、头孢孟多酯钠
碳青酶烯类	3	美罗培南、亚胺培南-西司他丁钠、厄他培南
单环类	1	氨曲南
氨基糖苷类	2	硫酸异帕米星、硫酸依替米星
大环内酯类	2	红霉素、阿奇霉素
喹诺酮类	3	环丙沙星、左氧氟沙星、莫西沙星
多肽类	1	万古霉素
硝基咪唑类	3	甲硝唑、奥硝唑、替硝唑
恶唑酮类	1	利奈唑胺

抗菌药物类别	种类数/种	药物名称
青霉素类	2	美洛西林-舒巴坦、哌拉西林-他唑巴坦
头孢菌素类	8	头孢替安、头孢曲松、头孢呋辛、头孢美唑、头孢替唑、头孢唑林、头孢哌酮-舒巴坦、头孢孟多酯钠
碳青酶烯类	3	美罗培南、亚胺培南-西司他丁钠、厄他培南
单环类	1	氨曲南
氨基糖苷类	2	硫酸异帕米星、硫酸依替米星
大环内酯类	2	红霉素、阿奇霉素
喹诺酮类	3	环丙沙星、左氧氟沙星、莫西沙星
多肽类	1	万古霉素
硝基咪唑类	3	甲硝唑、奥硝唑、替硝唑
恶唑酮类	1	利奈唑胺

抗菌药物	累计计量/g	用药天数/d	DDD值	DDDs	DUI
头孢美唑	1 316.0	299	1.50	877.3	2.93
莫西沙星	172.0	405	0.40	430.0	1.06
阿奇霉素	164.5	315	0.50	329.0	1.04
哌拉西林-他唑巴坦	4 392.0	357	13.50	325.3	0.91
左氧氟沙星	132.5	238	0.50	265.0	1.11
美洛西林-舒巴坦	1 035.0	147	6.75	153.3	1.04
头孢替安	144.5	48	1.00	144.5	3.01
头孢曲松	246.0	54	2.00	123.0	2.28
美罗培南	168.0	122	1.50	112.0	0.92
头孢呋辛	195.0	60	2.25	86.7	1.45

抗菌药物	累计计量/g	用药天数/d	DDD值	DDDs	DUI
头孢美唑	1 316.0	299	1.50	877.3	2.93
莫西沙星	172.0	405	0.40	430.0	1.06
阿奇霉素	164.5	315	0.50	329.0	1.04
哌拉西林-他唑巴坦	4 392.0	357	13.50	325.3	0.91
左氧氟沙星	132.5	238	0.50	265.0	1.11
美洛西林-舒巴坦	1 035.0	147	6.75	153.3	1.04
头孢替安	144.5	48	1.00	144.5	3.01
头孢曲松	246.0	54	2.00	123.0	2.28
美罗培南	168.0	122	1.50	112.0	0.92
头孢呋辛	195.0	60	2.25	86.7	1.45

合用类别	例数	联合用药类别	累计例数
大环内酯类合用	74	β-内酰胺类	60
		碳青酶烯类	8
		氨基糖苷类	4
		喹诺酮类	2
喹诺酮类合用	66	β-内酰胺类	48
		碳青酶烯类	8
		氨基糖苷类	4
		噁唑烷酮类	4
		糖肽类	2
β-内酰胺类合用	20	β-内酰胺类	10
		氨基糖苷类	6
		糖肽类	3
		噁唑烷酮类	1

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 13

Related Articles 15

Recommended Articles

Metrics

[1]	GAO Zikang, CHEN Jing. Construction of a nomogram prediction model for the prognosis of patients with depressive disorder based on the characteristics of peripheral blood lymphocyte subsets [J]. Laboratory Medicine, 2025, 40(12): 1146-1152.
[2]	WANG Tian, ZHANG Yun, BAI Yi, ZHAI Weibin, ZHAO Hai. Roles of PIV，SII and NPAR in the diagnosis of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites [J]. Laboratory Medicine, 2025, 40(12): 1153-1158.
[3]	HUANG Ting, XU Yan, SHI Qingxing, PENG Ying. Roles of miR-944 and MARCH7 mRNA in prognosis assessment of non-small cell lung cancer patients [J]. Laboratory Medicine, 2025, 40(12): 1159-1164.
[4]	LI Minghong, MIN Cuili, GUO Qingbo, MA Lujuan. Predictive roles of serum 25（OH）D and SAA for the response to immunosuppressive therapy in autoimmune hepatitis [J]. Laboratory Medicine, 2025, 40(12): 1165-1170.
[5]	ZHEN Di, JIA Bin, MENG Xianyi. Roles of serum sPD-1 and sTWEAK levels in patients with ulcerative colitis in disease monitoring and prognosis assessment [J]. Laboratory Medicine, 2025, 40(12): 1171-1176.
[6]	ZHAO Yilin, XU Yan, YIN Hui. Roles of serum miR-145-5p，miR-200C-3p and miR-1290 in prognosis assessment of patients with papillary thyroid carcinoma [J]. Laboratory Medicine, 2025, 40(12): 1177-1182.
[7]	LI Song, XIANG Xu. Risk factors for poor prognosis in elderly patients with severe fever and thrombocytopenia syndrome and their clinical significance [J]. Laboratory Medicine, 2025, 40(12): 1183-1189.
[8]	CHANG Nan, WEI Yali, LU Qifeng, LI Tian, HOU Tingting, LI Yuan, ZHU Mengyu, SHEN Yajuan. A machine learning early warning model for acute promyelocytic leukemia based on blood cell analyzer parameters [J]. Laboratory Medicine, 2025, 40(12): 1190-1196.
[9]	. [J]. Laboratory Medicine, 2025, 40(12): 1197-1202.
[10]	. [J]. Laboratory Medicine, 2025, 40(12): 1216-1221.
[11]	. [J]. Laboratory Medicine, 2025, 40(12): 1222-1226.
[12]	BAO Wen. Application and prospect of microsatellite instability determination in tumor diagnosis and treatment [J]. Laboratory Medicine, 2025, 40(12): 1227-1231.
[13]	XIONG Ying, GUO Wei. From generic to personalized：the evolution and frontiers of indirect methods for establishing reference interval [J]. Laboratory Medicine, 2025, 40(11): 1035-1041.
[14]	CHEN Yanqin, FAN Lina, YANG Dagan. Six indirect method algorithms for establishing the reference range of serum cystatin C for adults in Hangzhou and consistency analysis [J]. Laboratory Medicine, 2025, 40(11): 1047-1052.
[15]	LIU Chunyan, NIU Shumin, DENG Zhaohui, LIANG Mengjie, ZHANG Xin. Establishing the reference ranges for AFP，CEA，CA72-4 and CA19-9 in Urumqi region by indirect method [J]. Laboratory Medicine, 2025, 40(11): 1053-1058.